CD274 and melanoma: Although older patients are more likely to die from reasons other than melanoma, a prior study of 254 melanoma patients treated with anti-PD-1 (92.5%) or anti-PD-L1 (7.5%) found similar survival (OS; PFS) regardless of the patient’s age.